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The media has reported several neonatal death events re-
cently, and it is suspected that these events are related to 
improper vaccination. This is a deeply regrettable occur-
rence. Regarding the current situation, we suggest relevant 
national departments lead and organize experts in areas of 
clinical medicine, epidemiology, disease control, legal 
medicine, pharmacy, bio-product research and development, 
quality control and other related fields to establish a joint 
investigation team to conduct an investigation quickly and 
independently to determine the causes as soon as possible to 
reassure the public. Currently, the public is focused on 
whether the vaccine is safe. Therefore, it should be first 
made clear whether the deaths were caused by vaccination. 
If so, what was the cause of death? If not, the causes result-
ing in death should be identified. These might be quite 
complex, therefore the investigation should be thorough and 
meticulous, involving vaccine production, quality inspec-
tion, supervision, distribution, transportation, storage, vac-
cination and other processes. The situation of vaccinating 
newborns should also be investigated, including whether 
they have other concurrent diseases, changes in vital signs 
and exact causes of death, to ensure that all evidence is true, 
scientific and fair. We can take targeted measures to prevent 
this kind of tragedy from happening again only after deter-
mining the exact causes of death. There are many hepatitis 
B cases in China and vaccination is the most effective 
means of prevention. From the 1990s onwards, hepatitis B 
vaccination has been popular and has significantly reduced 
the hepatitis B infection rate of the newborn population in 
China. Furthermore, in recent years in China, a very well 
developed system has been formed for hepatitis B vaccine 
from R&D to production, vaccination and supervision. 
Generally speaking, hepatitis B vaccination is safe and ef-
fective. It is essential to receive vaccination to prevent hep-
atitis B infection. Therefore, it is critical to determine the 
truth behind the neonatal deaths following vaccination. We 
should not take these events lightly, or give up on hepatitis 
B vaccination because of the potential of slight risks. The 





Professor Li LanJuan, a M.D. supervisor, academician of the CAE (Chinese Academy of Engineering) and chief physician of 
the First Affiliated Hospital of Zhejiang University, is a famous infectious disease specialist in China and she has been en-
gaged in clinical, teaching and scientific research work in the field of infectious diseases for 40 years. She is a pioneer in the 
study of artificial liver in China and established a special and effective artificial liver system (Li’s artificial liver system 
(Li-ALS)), which was a momentous breakthrough in the treatment of severe hepatitis. Professor Li has also made great 
achievements in microecology research by developing new infectious microecology theories that explore the occurrence, de-
velopment, and outcome of infection from the microecological perspective, and by proposing new strategies for the pre- 
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vention and control of infections. In addition, she has undertaken more than 10 key research pro-
jects such as the national science fund project, National High Technology Research and Devel-
opment Program of China and National Basic Research Program of China and so on. She has 22 
authorized invention patents and has published more than 400 papers, over 150 collected by SCI 
academic journals including The Lancet and The New England Journal of Medicine. Served as the 
first completed, she has won several prizes including first prize of National Science and Technol-
ogy Progress, and second prize of National Science and Technology Progress twice, first prizes of 
Science and Technology Progress of Zhejiang Province five times, and the second prize of Popu-
larization and Application of Award in Colleges and Universities granted by the Ministry of Edu-
cation. Presently, she holds the post of director of the State Key Laboratory for the Diagnosis of 
Infectious Diseases, the Leader of State Key Discipline Department of Internal Medicine (Infec-
tious Diseases), and also director of the Zhejiang Infectious Disease Key Laboratory.  
Meanwhile, she is also the director of the Department of Bio-Medicine of the Ministry of Education, vice chairman of the 
Chinese Medical Association (CMA), vice president of the Chinese Health Information Society (CHIA), deputy chairman of 
the Chinese Society of Biomedical Engineering (CSBE), and director of the National Artificial Liver Training Base, division 
chief of the Microecology Branch of Chinese Preventive Medicine Association (CPMA), division chief of the Infectious Dis-
eases Branch of Chinese Medical Doctor Association (CDMA), a vice-chairman member of the Third Cloud Computing Ex-
pert Committee of Chinese Institute of Electronics (CIE), chairman of the International Human Microbiome Consortium 
(IHMC), board trustees of the International Society for Apheresis (ISFA), president of Zhejiang Medical Association, edi-
tor-in-chief of the Chinese Journal of Clinical Infectious Diseases, Chinese Journal of Microecology and Zhejiang Medical 
Journal, vice editor-in-chief of the Chinese Journal of Infectious Diseases and International Journal of Epidemiology and 
Infectious Disease. She has edited and published 28 monographs including the first edition of “Artificial Liver” and “Infec-
tious Microecology” of China; and planned textbooks of Epidemiology. Furthermore, she also holds the position of vice chief 
engineer of the “Twelfth Five-Year Plan”—a major science-technology project titled “Prevention and Treatment of AIDS and 
Viral Hepatitis and Other Major Infectious Diseases” and is the expert team leader of “Field Study at Comprehensive Preven-
tion and Control Demonstration Area”. In 2010, she won the title of “National Excellent Science and Technology Workers” 
for her great contribution to the diagnosis and treatment of infectious disease. 
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